Early Breast Development: Premature Thelarche or Progressive Central Precocity?
A 7-year-old girl presents with breast budding for 6 months. Height is 128 cm (SDS +1.5), growth velocity 8 cm/year, and bone age 9.5 years. She has no pubic hair, no vaginal bleeding, and no headaches. Pelvic ultrasound shows a uterus 4 cm long and no ovarian cysts. Baseline LH is 0.6 mIU/mL and estradiol 20 pg/mL. Her mother had menarche at 11 years. The family asks whether she has precocious puberty and whether treatment will make her shorter or taller. The pediatrician is considering a GnRH stimulation test but is unsure because LH is not clearly elevated.
1. Interpret the findings. How likely is central precocious puberty versus premature thelarche?
Read the worked answer
The findings are concerning for progressive central precocious puberty rather than isolated premature thelarche. Breast budding before age 8 is early, but the key additional features are growth acceleration (8 cm/year), bone age advanced by about 2.5 years, and a pubertal-sized uterus. Isolated premature thelarche usually shows slow growth, minimal bone age advancement, and a prepubertal uterus. A baseline LH of 0.6 mIU/mL is not clearly pubertal in all assays, and estradiol of 20 pg/mL is nonspecific, so the baseline labs do not exclude central precocity. The absence of pubic hair and menses does not rule it out. The family history of menarche at 11 is not protective. I would proceed with a GnRH stimulation test rather than observe.
2. What is the role of GnRH stimulation and MRI? When would you treat?
Read the worked answer
GnRH stimulation is the best way to confirm central activation. A pubertal LH response after GnRH agonist stimulation supports central precocious puberty. If the response is prepubertal and growth remains slow, observation is reasonable. If central precocity is confirmed, MRI is indicated to look for hypothalamic or pituitary lesions, especially because she is under 8 years old and has progressive signs. Treatment with a GnRH agonist is considered when puberty is progressive and predicted adult height is compromised. The goals are to pause pubertal progression, slow bone age advancement, and preserve adult height. Treatment is not indicated for isolated premature thelarche. In this girl, the growth velocity and bone age already suggest a height benefit from treatment if central precocity is confirmed.
3. How would you counsel the family about treatment goals and monitoring?
Read the worked answer
I would explain that early breast development alone is common, but her fast growth and advanced bone age mean we need to check whether the brain has started puberty too early. If it has, treatment can pause puberty and may preserve adult height, but it will not make her taller than her genetic potential. Treatment involves regular injections and monitoring of growth, pubertal signs, bone age, and sometimes pelvic ultrasound. I would also discuss possible side effects such as injection-site reactions and temporary mood changes. If MRI is needed, I would explain that most cases in girls are idiopathic, but imaging is important to rule out a structural cause. I would reassure the family that the decision will be based on test results and progression, not on a single LH value.